Most Read Articles
Pearl Toh, 2 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 4 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Infliximab use tied to reversal of clotting abnormalities in IBD patients

06 Oct 2020

Treatment with infliximab to control inflammation effectively reduces parameters that are associated with a higher risk of venous thromboembolism in patients with inflammatory bowel disease (IBD), results of a study have shown.

Sixty-two patients with active IBD initiating infliximab, vedolizumab, or methylprednisolone and 22 health controls were included in this prospective study. The investigators collected plasma before (w0) and after induction therapy (w14).

Clot lysis assay was used to determine amplitude (marker for clot intensity), time to peak (Tmax; marker for clot formation rate), area under the curve (AUC; global marker for coagulation/fibrinolysis), and 50-percent clot lysis time (50%CLT; marker for fibrinolytic capacity). Plasminogen activator inhibitor-1 (PAI-1) and fibronectin were measured using ELISA. Clinical remission was assessed at w14.

AUC, amplitude and 50%CLT at baseline were significantly higher in IBD patients than in healthy controls. In 34 remitters, AUC (165 percent vs 97 percent; p=0.001), amplitude (119 percent vs 95 percent; p=0.002), and 50%CLT (122 percent vs 100 percent; p=0.001) were reduced significantly and even normalized to healthy control level.

An inverse association was found between vedolizumab trough concentration and fibronectin concentration (r, –0.732; p=0.002). The increase in Tmax for infliximab-treated remitters showed a significant difference from the decrease in Tmax for vedolizumab-treated remitters (p=0.028). Moreover, the 50%CLT increased (p=0.038) when remitters were concomitantly treated with methylprednisolone.

“Active IBD represent an independent risk factor for venous thromboembolism,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 4 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.